A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as monotherapy for adults with treatment-resistant depression, Johnson & Johnson ...

In the first 22 months of a mavacamten REMS program, few patients needed a temporary interruption in treatment for LVEF below 50%.

JMP Securities reiterated its Market Outperform rating and $78.00 price target for Cytokinetics shares (NASDAQ:CYTK). This affirmation comes despite the stock experiencing a significant drop on ...

However, Spravato remains restricted under the FDA's REMS program due to its abuse potential. Investors will watch how this regulatory win impacts Johnson & Johnson's pharma segment ahead of earnings.

President Donald Trump issued executive orders late Friday reviving some of his first term’s anti-abortion policies, like ...

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a ...

Heart failure may cause symptoms such as: Due to the risk of heart failure, Camzyos is available through a risk evaluation and mitigation strategies (REMS) program only. The FDA requires REMS ...

Thus, FDA generally directs healthcare professionals ... (as long as the prescriber enrolls in the REMS). Via its patient support program, Requestor arranges for the patient’s vaccination ...